Trials / Unknown
UnknownNCT02403440
A Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients
A Safety, Pharmacokinetics and Pharmacodynamics Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to obtain information on efficacy, safety and Pharmacokinetics (PK)/Pharmacodynamics (PD) of Hetrombopag over 14 days in Chinese patients with chronic ITP.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Hetrombopag Olamine | Hetrombopag Olamine 2.5mg, 5mg and 7.5mg |
Timeline
- Start date
- 2014-04-01
- Primary completion
- 2015-04-01
- First posted
- 2015-03-31
- Last updated
- 2015-03-31
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02403440. Inclusion in this directory is not an endorsement.